B cell-depleting CAR T cells have been repurposed as a treatment for B cell-mediated autoimmune diseases, with the first using an anti-CD19 scFv CAR for systemic lupus erythematosus (SLE) (Figure 1A). This evidence concerns the gene CD19 and systemic lupus erythematosus.